Telomere erosion in NF1 tumorigenesis

Oncotarget

Volumn 8, Issue 25, 2017, Pages 40132-40139

  Jones, Rhiannon E ^a   Grimstead, Julia W ^a   Sedani, Ashni ^a   Baird, Duncan ^a   Upadhyaya, Meena ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Cancer; Genetic instability; MPNST; NF1; Telomere

Indexed keywords

ARTICLE; CANCER PROGNOSIS; CARCINOGENESIS; CHROMOSOME ANALYSIS; CHROMOSOME DAMAGE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CUTANEOUS NEUROFIBROMA; DIFFUSED PLEXIFORM NEUROFIBROMA; DISEASE ASSOCIATION; GENOMIC INSTABILITY; HUMAN; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MOLECULAR CLONING; NEUROFIBROMA; NEUROFIBROMATOSIS TYPE 1; SKIN CANCER; SKIN CARCINOGENESIS; TELOMERE; TELOMERE LENGTH; X CHROMOSOME; Y CHROMOSOME; CANCER GRADING; COMPARATIVE GENOMIC HYBRIDIZATION; GENETICS; HETEROZYGOSITY LOSS; NEURILEMOMA; PATHOLOGY; TELOMERE SHORTENING;

NEUROFIBROMIN;

CARCINOGENESIS; COMPARATIVE GENOMIC HYBRIDIZATION; HUMANS; LOSS OF HETEROZYGOSITY; NEOPLASM GRADING; NEURILEMMOMA; NEUROFIBROMA; NEUROFIBROMATOSIS 1; NEUROFIBROMIN 1; TELOMERE; TELOMERE SHORTENING;

EID: 85020977405     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.16981     Document Type: Article

References (59)

1. Brems H, Beert E, de Ravel T, Legius E. Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1. Lancet Oncol. 2009; 10:508-15
2. Evans DG, Baser ME, McGaughran H, Sharif S, Howard E, Moran A. Malignant Peripheral Nerve Sheath Tumours in Neurofibromatosis Type 1. Journal of Medical Genetics. 2002; 39:311-14
3. Spurlock G, Knight SJ, Thomas N, Kiehl TR, Guha A, Upadhyaya M. Molecular evolution of a neurofibroma to a malignant peripheral nerve sheath tumour (MPNST) in an NF1 patient:correlation between histopathological, clinical and molecular findings. J Cancer Res Clin Oncol. 2010; 136:1869-80
4. Beert E, Brems H, Daniëls B, De Wever I, Van Calenbergh F, Schoenaers J, Debiec-Rychter M, Gevaert O, De Raedt T, Van Den Bruel A, de Ravel T, Cichowski K, Kluwe L, et al. Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors. Genes Chromosomes Cancer. 2011; 50:1021-32
5. Upadhyaya M, Cooper DN. Neurofibromatosis type 1; molecular and cellular biology. Upadhyaya and Cooper, Springer. 2012
6. Tucker T, Wolkenstein P, Revuz J, Zeller J, Friedman J. Association between benign and malignant peripheral nerve sheath tumors in NF1. Neurology. 2005; 5:205-11
7. Mautner VF, Kluwe L, Friedrich RE, Roehl AC, Bammert S, Högel J, Spöri H, Cooper DN, Kehrer-Sawatzki H. Clinical characterisation of 29 neurofibromatosis type-1 patients with molecularly ascertained 1.4 Mb type-1 NF1 deletions. J Med Genet. 2010; 47:623-30
8. Ferner RE, Hughes RA, Hall SM, Upadhyaya M, Johnson MR. Neurofibromatous neuropathy in neurofibromatosis 1 (NF1). J Med Genet. 2004; 41:837-41
9. Evans DG, Huson SM, Birch JM. Malignant peripheral nerve sheath tumours in inherited disease. Clin Sarcoma Res. 2012; 2:17
10. Miller SJ, Rangwala F, Williams J, Ackerman P, Kong S, Jegga AG, Kaiser S, Aronow BJ, Frahm S, Kluwe L, Mautner V, Upadhyaya M, Muir D, et al. Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. Cancer Res. 2006; 66:2584-91
11. Mantripragada KK, Spurlock G, Kluwe L, Chuzhanova N, Ferner RE, Frayling IM, Dumanski JP, Guha A, Mautner V, Upadhyaya M. High-resolution DNA copy number profiling of malignant peripheral nerve sheath tumors using targeted microarray-based comparative genomic hybridization. Clin Cancer Res. 2008; 14:1015-24
12. Mantripragada KK, Díaz de Ståhl T, Patridge C, Menzel U, Andersson R, Chuzhanova N, Kluwe L, Guha A, Mautner V, Dumanski JP, Upadhyaya M. Genome-wide highresolution analysis of DNA copy number alterations in NF1-associated malignant peripheral nerve sheath tumors using 32K BAC array. Genes Chromosomes Cancer. 2009; 48:897-907
13. Miller SJ, Jessen WJ, Mehta T, Hardiman A, Sites E, Kaiser S, Jegga AG, Li H, Upadhyaya M, Giovannini M, Muir D, Wallace MR, Lopez E, et al. Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. EMBO Mol Med. 2009; 1:236-48
14. Hummel TR, Jessen WJ, Miller SJ, Kluwe L, Mautner VF, Wallace MR, Lázaro C, Page GP, Worley PF, Aronow BJ, Schorry EK, Ratner N. Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin. Clin Cancer Res. 2010; 16:5048-57
15. Upadhyaya M, Spurlock G, Thomas L, Thomas NS, Richards M, Mautner VF, Cooper DN, Guha A, Yan J. Microarray-based copy number analysis of neurofibromatosis type-1 (NF1)-associated malignant peripheral nerve sheath tumors reveals a role for RhoGTPase pathway genes in NF1 tumorigenesis. Hum Mutat. 2012; 33:763-76
16. Meany H, Dombi E, Reynolds J, Whatley M, Kurwa A, Tsokos M, Salzer W, Gillespie A, Baldwin A, Derdak J, Widemann B. 18-fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation of nodular lesions in patients with Neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST). Pediatr Blood Cancer. 2013; 60:59-64
17. Mo W, Chen J, Patel A, Zhang L, Chau V, Li Y, Cho W, Lim K, Xu J, Lazar AJ, Creighton CJ, Bolshakov S, McKay RM, et al. CXCR4/CXCL12 mediate autocrine cell-cycle progression in NF1-associated malignant peripheral nerve sheath tumors. Cell. 2013; 152:1077-90
18. Rahrmann EP, Watson AL, Keng VW, Choi K, Moriarity BS, Beckmann DA, Wolf NK, Sarver A, Collins MH, Moertel CL, Wallace MR, Gel B, Serra E, et al. Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. Nat Genet. 2013; 45:756-66
19. De Raedt T, Beert E, Pasmant E, Luscan A, Brems H, Ortonne N, Helin K, Hornick JL, Mautner V, Kehrer-Sawatzki H, Clapp W, Bradner J, Vidaud M, et al. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature. 2014; 514:247-51
20. Lee W, Teckie S, Wiesner T, Ran L, Prieto Granada CN, Lin M, Zhu S, Cao Z, Liang Y, Sboner A, Tap WD, Fletcher JA, Huberman KH, et al. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet. 2014; 46:1227-32
21. Zhang M, Wang Y, Jones S, Sausen M, McMahon K, Sharma R, Wang Q, Belzberg AJ, Chaichana K, Gallia GL, Gokaslan ZL, Riggins GJ, Wolinksy JP, et al. Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors. Nat Genet. 2014; 46:1170-2
22. de Lange T. Shelterin: The protein complex that shapes and safeguards human telomeres. Genes Dev. 2005; 19:2100-2110
23. Counter CM, Avilion AA, LeFeuvre CE, Stewart NG, Greider CW, Harley CB, Bacchetti S. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J. 1992; 11:1921-9
24. Jones RE, Oh S, Grimstead JW, Zimbric J, Roger L, Heppel NH, Ashelford KE, Liddiard K, Hendrickson EA, Baird DM. Escape from telomere-driven crisis is DNA ligase III dependent. Cell Rep. 2014; 8:1063-76
25. Artandi SE, Chang S, Lee SL, Alson S, Gottlieb GJ, Chin L, DePinho RA. Telomere dysfunction promotes nonreciprocal translocations and epithelial cancers in mice. Nature. 2000; 406: 641-645
26. Lin TT, Norris K, Heppel NH, Pratt G, Allan JM, Allsup DJ, Bailey J, Cawkwell L, Hills R, Grimstead JW, Jones RE, Britt-Compton B, Fegan C, et al. Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease. Br J Haematol. 2014; 167:214-223
27. Strefford JC, Kadalayi L, Forster J, Rose-Zerilli MJ, Parker A, Lin TT, Heppel NH, Norris K, Gardiner A, Davies Z, Gonzalez de Castro D, Else M, Steele AJ, et al. Telomere length predicts progression and overall survival in chronic lymphocytic leukemia: data from the UK LRF CLL4 trial. Leukemia. 2015; 29:2411-14
28. Simpson K, Jones RE, Grimstead JW, Hills R, Pepper C, Baird DM. Telomere fusion threshold identifies a poor prognostic subset of breast cancer patients. Mol Oncol. 2015; 9:1186-1193
29. Mantripragada KK, Caley M, Stephens P, Jones CJ, Kluwe L, Guha A, Mautner V, Upadhyaya M. Telomerase activity is a biomarker for high grade malignant peripheral nerve sheath tumors in neurofibromatosis type 1 individuals. Genes Chromosomes Cancer. 2008; 47:238-46
30. Lin TT, Letsolo BT, Jones RE, Rowson J, Pratt G, Hewamana S, Fegan C, Pepper C, Baird DM. Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia:evidence for a telomere crisis. Blood. 2010; 116:1899-1907
31. Spurlock G, Griffiths S, UffJ, Upadhyaya M. Somatic alterations of the NF1 gene in an NF1 individual with multiple benign tumours (internal and external) and malignant tumour types. Fam Cancer. 2007; 6:463-71
32. Upadhyaya M, Kluwe L, Spurlock G, Monem B, Majounie E, Mantripragada K, Ruggieri M, Chuzhanova N, Evans DG, Ferner R, Thomas N, Guha A, Mautner V. Germline and somatic NF1 gene mutation spectrum in NF1-associated malignant peripheral nerve sheath tumours (MPNSTs). Hum Mutat. 2008; 29:74-82
33. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW. Specific association of human telomere activity with immortal cells and culture. Science. 1994; 266:2011-5
34. Hastie ND, Dempster M, Dunlop MG, Thompson M, Green DK, Allshire RC. Telomere reduction in human colorectal carcinoma and with ageing. Nature. 1990; 346:866-8
35. Zhu X, Han W, Xue W, Zon Y, Xie C, Du J, Jin G. The association between telomere length and cancer risk in population studied. Sci Rep. 2016; 6:222
36. Frías C, García-Aranda C, De Juan C, Morán A, Ortega P, Gómez A, Hernando F, López-Asenjo JA, Torres AJ, Benito M, Iniesta P. Telomere shortening is associated with poor prognosis and telomerase activity correlates with DNA repair impairment in non-small cell lung cancer. Lung Cancer. 2008; 60:416-425
37. Roger LR, Jones E, Heppel NH, Williams GT, Sampson JR, Baird DM. Extensive telomere erosion in the initiation of colorectal adenomas and its association with chromosomal instability. J Natl Cancer Inst. 2013; 105:1202-1211
38. Hurwitz LM, Heaphy CM, Joshu CE, Isaacs WB, Konishi Y, De Marzo AM, Isaacs SD, Wiley KE, Platz EA, Meeker AK. Telomere length as a risk factor for hereditary prostate cancer. Prostate. 2014; 74:359-64
39. Zhou X, Meeker AK, Makambi KH, Kosti O, Kallakury BV, Sidawy MK, Loffredo CA, Zheng YL. Telomere length variation in normal epithelial cells adjacent to tumor: potential biomarker for breast cancer local recurrence. Carcinogenesis. 2012; 33:113-8
40. Terry KL, Tworoger SS, Vitonis AF, Wong J, Titus-ErnstoffL, De Vivo I, Cramer DW. Telomere length and genetic variation in telomere maintenance genes in relation to ovarian cancer risk. Cancer Epidemiol Biomarkers Prev. 2012; 21:504-12
41. Barrett JH, Iles MM, Dunning AM, Pooley K. Telomere length and common disease: study design and analytical challenges. Hum Genetics. 2015; 134:679-689
42. Dubbink HJ, Bakels H, Post E, ZwarthoffEC, Verdijk RM. TERT promoter mutations and BRAF mutations are rare in sporadic, and TERT promoter mutations are absent in NF1-related malignant peripheral nerve sheath tumours. J Neurooncol. 2014; 120:267-72
43. Thomas L, Mautner VF, Cooper D, Upadhyaya M. Molecular Heterogeneity in Malignant Peripheral Nerve Sheath Tumors (MPNSTs) Associated with Neurofibromatosis Type 1 (NF1). Hum Genomics. 2012; 6:18-27
44. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366:883-92
45. Jones CH, Pepper C, Baird DM. Telomere dysfunction and its role in haematological cancer. Br J Haematol. 2012; 156:573-87
46. Chin K, de Solorzano CO, Knowles D, Jones A, Chou W, Rodriguez EG, Kuo WL, Ljung BM, Chew K, Myambo K, Miranda M, Krig S, Garbe J, et al. In situ analyses of genome instability in breast cancer. Nat Genet. 2004; 36:984-8
47. Meeker AK, Argani P. Telomere shortening occurs early during breast tumorigenesis: a cause of chromosome destabilization underlying malignant transformation? J Mammary Gland Biol Neoplasia. 2004; 9:285-96
48. Pepper C, Baird DM. Shortened telomeres:a driving force behind leukemia? Future Oncology. 2010; 6:1681-1686
49. Cichowski K, Jacks T. NF1 tumor suppressor gene function: narrowing the GAP. Cell. 2001; 104:593-604
50. Nielsen GP, Stemmer-Rachamimov AO, Ino Y, Moller MB, Rosenberg AE, Louis DN. Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. Am J Pathol. 1999; 155:187984
51. Perrone F, Tabano S, Colombo F, Dagrada G, Birindelli S, Gronchi A, Colecchia M, Pierotti MA, Pilotti S. p15INK4b, p14ARF, and p16INK4a inactivation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. Clin Cancer Res. 2003; 9:4132-8
52. Frahms S, Mautner V, Brems L, Legius E, Debiec-Rychter M, Friedrich RE, Knofel WT, Peiper M, Kluwe L. Genetic and phenotypic characterisation of tumour cells derived from malignant peripheral nerve sheath tumours of neurofibromatosis type-1 patients. Neurobiol Dis. 2004; 16:85-91
53. Sabah M, Cummins R, Leader M, Kay E. Loss of p16 (INK4A) expression is associated with allelic imbalance/loss of heterozygosity of chromosome 9p21 in microdissected malignant peripheral nerve sheath tumors. Appl Immunohistochem Mol Morphol. 2006; 14:97-102
54. Legius E, Dierick H, Wu R, Hall B, Marynen P, Cassiman J, Glover T. TP53 mutations are frequent in malignant NF1 tumors. Genes Chrom Cancer. 1994; 10:250-255
55. Verdijk RM, den Bakker MA, Dubbink HJ, Hop WC, Dinjens WN, Kros JM. TP53 mutation analysis of malignant peripheral nerve sheath tumors. J Neuropathol Exp Neurol. 2010; 69:16-26
56. Latres E1, Drobnjak M, Pollack D, Oliva MR, Ramos M, Karpeh M, WoodruffJM, Cordon-Cardo C. Chromosome 17 abnormalities and TP53 mutations in adult soft tissue sarcomas. Am J Pathol. 1994; 145:345-55
57. Borras C, Gomez-Cabrera MC, Vina J. The dual role of p53: DNA protection and antioxidant. Free Radic Res. 2011; 45:643-652
58. WoodruffJM, Kourea HP, Louis DN, Scheithauer BW. Malignant nerve sheath tumor (MPNST). In: Kleihues P, Cavenee WK, editors. Pathology and Genetics of Tumours of the Nervous system. Lyon, France: IARC Press. 2000; pp.172-174
59. Capper R, Britt-Compton B, Tankimanova M, Rowson J, Letsolo B, Man S, Haughton M, Baird DM. The nature of telomere fusion and a definition of the critical telomere length in human cells. Genes Dev. 2007; 21:2495-508